Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06282120
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2024-02-21
Brief Title:
Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FULV Immunotherapy in First-line Gemsitabine Immunoprogressive Patients With Metastatic Biliary Tract Cancer
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FULV Immunotherapy in First-line Gemsitabine Immunoprogressive Patients With Metastatic Biliary Tract Cancer
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to test in biliary tract cancer patients The main questions it aims to answer are
To evaluate the efficacy of irinotecan liposome injection combined with 5-FULV immunotherapy for first-line gemsitabine immunoprogressive metastatic biliary tract cancer
To evaluate the safety of irinotecan liposome injection combined with 5-FULV immunotherapy for first-line gemsitabine immunoprogressive metastatic biliary tract cancer This study intends to use liposomal irinotecan combined with 5-FULV immunotherapy for second-line treatment of advanced biliary tract cancer that has progressed after gemsitabine immunotherapy to evaluate the efficacy and safety of this regimen with a view to providing better treatment options for second-line patients with advanced biliary tract cancer
To evaluate the efficacy of irinotecan liposome injection combined with 5-FULV immunotherapy for first-line gemsitabine immunoprogressive metastatic biliary tract cancer
To evaluate the safety of irinotecan liposome injection combined with 5-FULV immunotherapy for first-line gemsitabine immunoprogressive metastatic biliary tract cancer This study intends to use liposomal irinotecan combined with 5-FULV immunotherapy for second-line treatment of advanced biliary tract cancer that has progressed after gemsitabine immunotherapy to evaluate the efficacy and safety of this regimen with a view to providing better treatment options for second-line patients with advanced biliary tract cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None